Immunic, Inc. (IMUX), Thursday reported positive data from phase 1b study of IMU-856 for the treatment of celiac disease, a chronic digestive and autoimmune disorder.
A post hoc analysis of patients treated with IMU-856 showed a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1) levels.
"GLP-1, a hormone that occurs naturally in the gut, is released after eating and helps the body regulate blood sugar and satiety. It plays several critical roles, including triggering insulin release from the pancreas and blocking glucagon, a hormone raising blood sugar. Additionally, GLP-1 affects areas of the brain that process hunger and satiety," noted Hella Kohlhof, Chief Scientific Officer of Immunic.
IMU-856 also showed a dose-dependent reduction of body weight gain and food consumption in preclinical studies. These effects may indicate the potential for IMU-856 as an oral treatment option for weight management, the company said in a statement.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.